Amarantus Bioscience Holdings Inc. announced that it has appointed Curtis Scribner, MD MBA as Senior Vice President of Regulatory Affairs. Dr. Scribner brings over twenty years of US and worldwide regulatory development experience to Amarantus, and will focus primarily on accelerating worldwide regulatory pathways to market for Engineered Skin Substitute in the treatment of adult and pediatric severe burns, as well as Congenital Giant Hairy Nevus. Dr. Scribner is currently an independent regulatory consultant in the Bay Area.